Roche’s new AAN 2019 data Event
Overview of Roche key data at AAN covering new analysis from Ocrevus, satralizumab SakuraSky phase III data, risdiplam one year part I FIREFISH and SUNFISH data and dose selection data for the phase III study in Huntington's Disease
Roche Neuroscience and Rare Disease franchise update
Karl Mahler, Head of Investor Relations
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Karsten Jung, Therapeutic Area Head Neuroscience and Rare Diseases

Please register to access the replay*

*Privacy notice

Roche has hosted a live audio webcast and conference call on Monday, 13 May 2019.

Past IR Events
View more Events


Related links